Lamotrigine's Depressive-Pole Evidence Meets a Manic Breakthrough
A single patient, fully adherent and stable on lamotrigine for two years, now manic. Lamotrigine's trial evidence has always been strong for preventing depression and thin for mania — this breakthrough is that known asymmetry showing up, not a drug failure.
J.P. is a 29-year-old wedding photographer who has been on lamotrigine 200mg daily for two years with a genuinely excellent result: no depressive episodes at all in that stretch, a real change from the pattern before she started it, when depressive episodes had put her out of work for weeks at a time twice in three years. Wedding season runs from May through October for her, with long weekend shoots and irregular sleep built into the job every year. This week, three weekends into this season, her sister called her psychiatrist's office directly, worried: J.P. has been sleeping three hours a night for five days, talking about expanding her business into three additional cities by next spring, and put a down payment on $6,000 of new camera equipment without discussing it with her business partner first.
This is a manic episode, and it is breaking through while she is fully adherent to a drug that has otherwise protected her impressively well — which is confusing until the actual evidence for lamotrigine is laid out plainly: its trial data support real, meaningful efficacy for preventing depressive relapse in bipolar disorder, but it has never shown comparable efficacy for acute mania or for preventing manic episodes the way lithium, valproate, or the atypical antipsychotics do. Lamotrigine doing nothing to stop this manic episode is not a treatment failure in the sense of the drug not working — it is the asymmetry the trial data always predicted, showing up now for the first time simply because her first two years happened not to test the manic side of her illness.
Explaining a breakthrough on an otherwise-working drug
She has been so reliably well on this medication for two years that my first instinct is to ask what changed — did she miss doses, is there a new stressor, has something about her illness itself shifted? I want to understand why a drug that's worked this well suddenly isn't working before deciding what to do next.
Nothing changed, in the sense that matters here — she's adherent, and lamotrigine is doing exactly what its trial data always predicted it would do. It has real, robust evidence for depressive relapse prevention and essentially none for acute mania or manic prevention. This isn't a drug that stopped working, it's a drug being asked to do something it was never shown to do in the first place.
Her two clean years weren't lamotrigine protecting her from mania — they were two years where a manic episode simply didn't arise to test that gap. Wedding season and five nights of three hours of sleep is exactly the kind of trigger that would.
The practical answer isn't switching off lamotrigine — it's still doing real, valuable work on the depressive side that shouldn't be given up. It's adding an agent with actual antimanic efficacy on top of it, which is a completely normal shape for a long-term bipolar regimen to take: one drug covering each pole rather than expecting a single agent to cover both.
Quetiapine 100mg nightly started and titrating, added directly onto her unchanged lamotrigine 200mg daily. Her business partner was looped in, with her permission, to help delay the equipment purchase decision until her mood stabilizes. Follow-up scheduled at one week to assess acute response.
The team was explicit with her about what had actually happened: lamotrigine had not failed her, it had simply never been asked to cover the manic side of her illness before. Her long-term regimen going forward is expected to combine both drugs rather than lamotrigine alone, reflecting the different, non-overlapping evidence each one carries.